Impact of Fluid Management Within a Goal-directed Hemodynamic Protocol on Acid-base Balance in Elective Trauma Surgery (HIPSTER)
This study has been completed.
Sponsor:
Charite University, Berlin, Germany
Information provided by (Responsible Party):
Claudia Spies, Charite University, Berlin, Germany
ClinicalTrials.gov Identifier:
NCT01117519
First received: May 3, 2010
Last updated: November 15, 2011
Last verified: November 2011
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to determine whether the administration of a compound of balanced infusion solutions including 50% crystalloid and 50% colloid has a positive impact on acid-base balance in elective hip replacement surgery. The application of the study medication will be carried out through a goal-directed intraoperative therapy by transoesophageal doppler.
| Condition | Intervention | Phase |
|---|---|---|
|
Hemodynamic Instability |
Drug: Infusion Therapy |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator) Primary Purpose: Treatment |
| Official Title: | Impact of a Balanced Infusion Solution Compound of 50% Crystalloid and 50% Colloid Versus an Unbalanced Infusion Solution of 100% Crystalloid Within a Goal-directed Hemodynamic Protocol on Acid-base Balance |
Further study details as provided by Charite University, Berlin, Germany:
Primary Outcome Measures:
- Standard Base Excess [ Time Frame: up to 2 days ] [ Designated as safety issue: Yes ]After administration of 2 litres of study medication. In recovery room. On general ward.
Secondary Outcome Measures:
- SID (strong ion difference) [ Time Frame: up to 2 days ] [ Designated as safety issue: Yes ]Change of the SID (strong ion difference) according to the stewart-approach of evalutation acid-base-dysbalances
- Hemodynamic Stability [ Time Frame: up to 6 days ] [ Designated as safety issue: Yes ]Doses and duration of therapy with catecholamins, number and duration of hypotensive episodes
- Fluid Loss of Drainage [ Time Frame: up to 6 days ] [ Designated as safety issue: Yes ]The quantity of fluids per day losing by drainage during the first three days after surgery
- Discharge Criteria, Length of Hospital Stay [ Time Frame: 5 days up to hospital discharge ] [ Designated as safety issue: Yes ]Time until fullfilling the hospital discharge criteria (measured by the postanesthesia discharge scoring system (PADSS)), and length of hospital stay
- Organ Function/Dysfunction [ Time Frame: up to 6 days ] [ Designated as safety issue: Yes ](Cumulative) frequency of postoperative organ dysfunctions (cerebral, cardiac, pulmonary, renal, gastrointestinal)
- Incidence of Infections [ Time Frame: up to 5 days ] [ Designated as safety issue: Yes ]Perioperative Incidence of infections (according to the Centers of Disease and Prevention (CDC))
- Pain [ Time Frame: up to 6 days ] [ Designated as safety issue: Yes ]Pain of the patient measured by NAS (Numeric analogue scale), VAS (Visual analogue scale), NRS (Numeric rating scale) and BPS (Behavioral pain scale)
- Incidence of Delirium [ Time Frame: up to 6 days ] [ Designated as safety issue: Yes ]Incidence of delirium measured accordingly by DSM IV (Diagnostic and statistical manual of mental disorders criteria for delirium), Nu-DESC (Nursing delirium screening scale), DDS (Delirium detection score), CAM (Confusion assessment method), CAM-ICU (Confusion assessment method for the ICU), DRS (Delirium rating scale) and ICDSC (Intensive care delirium screening checklist).
- Incidence of Postoperative Cognitive Deficit (POCD) [ Time Frame: up to 90 days after surgery ] [ Designated as safety issue: Yes ]Measurement of cognitive function by 5 tests out of CANTAB (Cambridge neuropsychological test automated battery) modeled by the ISPOCD1 study (International study of post-operative cognitive dysfunction), Stroop colour word test(SCWT) and verbal learning test(VLT)
- Mobilisation [ Time Frame: up to 6 days ] [ Designated as safety issue: No ]Duration and type of mobilisation
| Enrollment: | 40 |
| Study Start Date: | May 2010 |
| Study Completion Date: | November 2011 |
| Primary Completion Date: | June 2011 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Active Comparator: unbalanced infusion solution |
Drug: Infusion Therapy
Based on changes of stroke volume measured by transoesophageal doppler patients during elective hip surgery will achieve either a unbalanced infusion solution, maximum dose of 100 ml/kg BW, or a compound of balanced infusion solution including 50% crystalloid and 50% colloid, each: maximum dose of 50 ml/kg BW. The study medication will be administered only during surgery.
|
| Active Comparator: balanced infusion solution compound |
Drug: Infusion Therapy
Based on changes of stroke volume measured by transoesophageal doppler patients during elective hip surgery will achieve either a unbalanced infusion solution, maximum dose of 100 ml/kg BW, or a compound of balanced infusion solution including 50% crystalloid and 50% colloid, each: maximum dose of 50 ml/kg BW. The study medication will be administered only during surgery.
|
Eligibility| Ages Eligible for Study: | 60 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Patients at the age of 60 and above who want to undergo an elective hip replacement surgery in the center of musculoskeletal surgery
- Offered patient information and written informed consent
Exclusion Criteria:
- Participation in another trial according to the German Drug Law 30 days to and during the study
- Lacking willingness to save and hand out data within the study
- Accommodation in an institution due to an official or judicial order
- (Unclear) history of alcohol or substances disabuse
- Absent knowledge of german language
- Analphabetism
- Allergy to hydroxyethyl starch or other ingredients of the intravenous solutions
- For women: Pregnancy or positive pregnancy test within the preoperative screening
- Operation due to case of emergency, polytrauma or pathologic fracture
- Only use of regional anaesthesia
- American Society of Anaesthesiologists (ASA) classification greater than III
- Peripheral or central edema
- AIDS (according to the CDC-classification of HIV-infection: category C)
- Rheumatoid disease under treatment with Anti-TNF-alpha-Ab and/or high-dose-corticoid-treatment
- Immunosuppression therapy
- History of bleeding tendency (e.g. von-Willebrand-disease, thrombocytopenia)
- Derailed metabolic disorder (e.g. Diabetes mellitus (Glucose > 300 mg/dl) during the preoperative screening)
- Known history of electrolyte disturbance (e.g. Hyperkalemia > 5.8 mmol/l, Hypernatraemia > 155 mmol/l)
- Known history of acid-base-dysbalances
- History of intracranial hemorrhage within one year of participation in the study
- Neurological or psychiatric disease with limited contractual capability
- Advanced disease of the oesophagus or upper respiratory tract
- Operation in the area of the oesophagus or nasopharynx within the last two months
- CHF (congestive heart failure) according to (New York Heart Association) classification - NYHA class IV
- Liver disease (CHILD B or C cirrhosis, end-stage liver disease (MELD-score greater than 10))
- Conditions after acute or chronic pancreatitis
- Renal insufficiency (serum creatinine greater than 2.0 mg/dl or greater than 150 µmol/l or dependency of haemodialysis)
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01117519
Locations
| Germany | |
| Dept. of Anaesthesiology and Intensive Care Medicine, Campus Charité Mitte, Charitéplatz 1 | |
| Berlin, Germany, 10117 | |
Sponsors and Collaborators
Charite University, Berlin, Germany
Investigators
| Principal Investigator: | Claudia Spies, Prof., MD | Charite University, Berlin, Germany |
More Information
No publications provided
| Responsible Party: | Claudia Spies, Prof. MD, Director of the Dept. of Anaesthesiology and Intensive Care Medicine, CVK, CCM, Charite University, Berlin, Germany |
| ClinicalTrials.gov Identifier: | NCT01117519 History of Changes |
| Other Study ID Numbers: | HIPSTER |
| Study First Received: | May 3, 2010 |
| Last Updated: | November 15, 2011 |
| Health Authority: | Germany: Federal Institute for Drugs and Medical Devices |
Keywords provided by Charite University, Berlin, Germany:
|
fluid and volume management acid-base balance goal-directed therapy transoesophageal doppler |
ClinicalTrials.gov processed this record on May 19, 2013